For research use only. Not for therapeutic Use.
Acazicolcept（Cat No.:I042185）is an investigational fusion protein designed to target and inhibit B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are involved in the activation and survival of B-cells. These molecules play a key role in autoimmune diseases such as systemic lupus erythematosus (SLE) and IgA nephropathy. By blocking BAFF and APRIL, acazicolcept aims to reduce B-cell-driven inflammation and immune system overactivity. It is being studied in clinical trials for its potential to treat autoimmune conditions, with a focus on improving disease outcomes and managing symptoms in affected patients.
| Catalog Number | I042185 |
| CAS Number | 2797026-97-0 |
| Purity | ≥95% |
